Transdermal patch maker gets FDA warning letter for subpotent product

FDA
Pocono Coated Products has received an FDA warning letter for faulty testing that led it to sell subpotent transdermal pain patches.

A North Carolina company that makes transdermal patches—as well as construction flashing tapes and a custom coating system for body armor—has gotten slapped on the wrist by the FDA for poor product testing which resulted in it releasing patches that were subpotent.

The FDA this week posted a warning letter that was sent to the Pocono Coated Products plant in Cherryville, North Carolina, after an inspection last year found problems with its processes. According to the letter, a customer of Pocono recalled all of the patches it got from the company after they determined that they might not meet release standards.

The FDA did not identify the customer, but there was a recall earlier this year of the Renovo Patch distributed by TMIG of Marietta, Georgia, after the FDA found the pain patch containing capsaicin and menthol was unapproved and also subpotent. The label of the patch indicated it was manufactured by Pocono.

Webinar

Bioavailability Enhancement – Industry Insights, Key Challenges & Advanced Development Solutions

Join this webcast on Tuesday, June 16 as experts present the exclusive survey findings and introduce innovative scalable drug delivery technologies proven to address the industry’s growing need for improving solubility and enhancing bioavailability.

The FDA faulted Pocono for releasing products without conducting or reviewing release testing to determine if the patches met the specifications. It said the company was not validating each step of its manufacturing process to see if products met specs.

“FDA test results demonstrating that your product was subpotent indicate that your un-validated manufacturing process is not capable of consistently delivering products that meet their specifications,” the letter said.

The FDA “strongly” recommended the company hire a consultant to help get its processes and testing in order. 

 

 

 

Suggested Articles

Novavax has inked a $60 million contract with the U.S. Department of Defense to help fund U.S.-based manufacturing of its COVID-19 vaccine candidate.

Vaccine maker Inovio has accused a longtime manufacturing partner of hampering its efforts to produce 1 million doses of a potential COVID-19 vaccine.

Roche's global manufacturing leader Pierre-Alain Ruffieux will take the reins and oversee the Moderna COVID-19 vaccine collaboration.